Progress, Potential, and Possibilities
Ira Pastor
All episodes
Best episodes
Seasons
Top 10 Progress, Potential, and Possibilities Episodes
Goodpods has curated a list of the 10 best Progress, Potential, and Possibilities episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Progress, Potential, and Possibilities for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Progress, Potential, and Possibilities episode by adding your comments to the episode page.
Dr. Francis Collins - Former Director, U.S. National Institutes Of Health (NIH); NIH Distinguished Investigator, Center for Precision Health Research, National Human Genome Research Institute - The Road To Wisdom
Progress, Potential, and Possibilities
09/16/24 • 55 min
Dr. Francis S. Collins, M.D., Ph.D., ( https://www.francisscollins.com/ ) is the former Director of the U.S. National Institutes of Health (NIH), where as the longest serving director of NIH (spanning 12 years and three presidencies) he oversaw the work of the largest supporter of biomedical research in the world, from basic to clinical research.
Dr. Collins continues to serve as NIH Distinguished Investigator,
Center for Precision Health Research, at the National Human Genome Research Institute ( NHGRI - https://irp.nih.gov/pi/francis-collins ).
Dr. Collins is a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the international Human Genome Project, which culminated in April 2003 with the completion of a finished sequence of the human DNA instruction book. He served as director of the National Human Genome Research Institute at the NIH from 1993-2008.
Dr. Collins' research laboratory has discovered a number of important genes, including those responsible for cystic fibrosis, neurofibromatosis, Huntington's disease, a familial endocrine cancer syndrome, and most recently, genes for type 2 diabetes, and the gene that causes Hutchinson-Gilford progeria syndrome, a rare condition that causes premature aging.
Dr. Collins received a B.S. in chemistry from the University of Virginia, a Ph.D. in physical chemistry from Yale University, and an M.D. with honors from the University of North Carolina at Chapel Hill. Prior to coming to the NIH in 1993, he spent nine years on the faculty of the University of Michigan, where he was a Howard Hughes Medical Institute investigator. He is an elected member of the Institute of Medicine and the National Academy of Sciences.
Dr. Collins was awarded the Presidential Medal of Freedom in November 2007 and the National Medal of Science in 2009.
Dr. Collins also founded and served as President of The BioLogos Foundation ( https://biologos.org/ ), which promotes discourse on the relationship between science and religion.
Dr. Collins is also an accomplished author with many available titles including The Language of Life: DNA and the Revolution in Personalized Medicine, The Language of God: A Scientist Presents Evidence for Belief, Music and Mind: Harnessing the Arts for Health and Wellness, and a new book coming out The Road to Wisdom: On Truth, Science, Faith, and Trust - Sep 17, 2024 ( https://www.amazon.com/Road-Wisdom-Truth-Science-Faith/dp/0316576301 ).
#FrancisCollins #NationalInstitutesOfHealth #HumanGenomeProject #NIH #Progeria #Cancer #Diabetes #Repurposing #Wisdom #Faith #Truth #Trust #BioLogosFoundation #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
Dr Dumazedier Kabasele, MD - Preventing, Treating And Beating Stroke in Democratic Republic of Congo
Progress, Potential, and Possibilities
05/22/22 • 24 min
Dr. Dumazedier Kabasele, MD, is the Founder of the Dumazedier Kabasele Foundation, a non-profit organization with a goal to raise awareness, and prevent, treat and beat stroke in the Democratic Republic of Congo (DRC). Dr. Kabasele earned his medical degree from the International Christian University in DRC, completed a special training fellowship in Neurology / Electro-Neurophysiology from the National Institute of Mental Health and Neuroscience in India, studied and trained in specialty stroke care at Hopistal Du Cinquantenaire (http://www.padiyathmedicitykinshasa.com/) in Kinshasa, DRC, where he currently practices care, and is completing a degree in Applied Health and Public Health at Brigham Young University (Idaho). Dr. Kabasele is highly passionate about vascular neurology and paralytic stroke care. He has appeared in various TV shows and talks to raise awareness about various neurological disorders in the DRC and believes strongly in transforming the world by giving hope to people and help them to have a better health and life.
Dr. Judith Campisi, Ph.D. - Professor of Biogerontology - Buck Institute for Research on Aging
Progress, Potential, and Possibilities
11/24/21 • 51 min
Dr. Judith Campisi, PhD (https://www.buckinstitute.org/lab/campisi-lab/) is a biochemist, cell biologist, and Professor of Biogerontology at the Buck Institute for Research on Aging. Dr. Campisi received a PhD in biochemistry from the State University of New York at Stony Brook and completed her postdoctoral training in cell cycle regulation at the Dana-Farber Cancer Institute and Harvard Medical School. As an assistant and associate professor at the Boston University Medical School, she studied the role of cellular senescence in suppressing cancer and soon became convinced that senescent cells also contributed to aging. She joined the Lawrence Berkeley National Laboratory as a senior scientist in 1991 working with Dr. Mina Bissell. In 2002, she started a second laboratory at the Buck Institute. At both institutions, Dr. Campisi established a broad program to understand the relationship between aging and age-related disease, with an emphasis on the interface between cancer and aging. Dr. Campisi is a member of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science. Dr. Campisi has received numerous awards for her research, including two MERIT awards from the National Institute on Aging and awards from the AlliedSignal Corporation, Gerontological Society of America, and American Federation for Aging Research. She is a recipient of the Longevity prize from the IPSEN Foundation, the Bennett Cohen award from the University of Michigan, and the Schober award from Halle University, and she is the first recipient of the international Olav Thon Foundation prize in Natural Sciences and Medicine. Dr. Campisi currently serves on advisory committees for the Alliance for Aging Research, Progeria Research Foundation, and NIA’s Intervention Testing Program. She is also an editorial board member for more than a dozen peer-reviewed journals. Dr. Campisi is a scientific founder of Unity Biotechnology, a California-based company focused on developing senolytic therapies for age-related pathologies. She has served on the scientific advisory boards of the Geron Corporation, Sierra BioScience, and Sangamo Biosciences.
Ben Novak, Lead Scientist, Revive & Restore - De-Extinction Biotechnology & Conservation Biology
Progress, Potential, and Possibilities
11/01/21 • 70 min
Ben Novak is Lead Scientist, at Revive & Restore (https://reviverestore.org/), a California-based non-profit that works to bring biotechnology to conservation biology with the mission to enhance biodiversity through the genetic rescue of endangered and extinct animals . Ben collaboratively pioneers new tools for genetic rescue and de-extinction, helps shape the genetic rescue efforts of Revive & Restore, and leads its flagship project, The Great Passenger Pigeon Comeback, working with collaborators and partners to restore the ecology of the Passenger Pigeon to the eastern North American forests. Ben uses his training in ecology and ancient-DNA lab work to contribute, hands-on, to the sequencing of the extinct Passenger Pigeon genome and to study important aspects of its natural history . Ben’s mission in leading the Great Passenger Pigeon Comeback is to set the standard for de-extinction protocols and considerations in the lab and field. His 2018 review article, “De-extinction,” in the journal Genes, helped to define this new term. More recently, his treatment, "Building Ethical De-Extinction Programs—Considerations of Animal Welfare in Genetic Rescue" was published in December 2019 in The Routledge Handbook of Animal Ethics: 1st Edition. Ben’s work at Revive & Restore also includes extensive education and outreach, the co-convening of seminal workshops, and helping to develop the Avian and Black-footed Ferret Genetic Rescue programs included in the Revive & Restore Catalyst Science Fund. Ben graduated from Montana State University studying Ecology and Evolution. He later trained in Paleogenomics at the McMaster University Ancient DNA Centre in Ontario. This is where he began his study of passenger pigeon DNA, which then contributed to his Master’s thesis in Ecology and Evolutionary Biology at the University of California Santa Cruz. This work also formed the foundational science for de-extinction. Ben also worked at the Australian Animal Health Laboratory–CSIRO (Commonwealth Scientific and Industrial Research Organisation) to advance genetic engineering protocols for the pigeon.
Viren Shah - VP & Chief Digital Officer, GE Appliances (Haier) - Creating Smart Home Ecosystems
Progress, Potential, and Possibilities
10/26/21 • 32 min
Mr. Viren Shah is Vice President & Chief Digital Officer, at GE Appliances (GEA - https://www.geappliances.com/), the American home appliance manufacturer, now a majority owned subsidiary of the Chinese multinational home appliances company, Haier (https://www.haierappliances.com/). Mr. Shah has been with GEA since October 2018, in which time he was appointed to lead the business through a digital transformation with a focus on data/intelligence at the center of gravity. Prior to becoming part of the Haier company, Mr. Shah was the CIO at Masco Cabinetry, and CIO Council Leader for their parent company, Masco Corporation, the international conglomerate manufacturer of products for the home improvement and new home construction markets. Mr. Shah has more than 20 years of global experience in creating business value using technology with a strong focus on customers for Fortune 10 organizations, such as his decade at the Walmart organization. He has contributed as a senior leader towards the success of startups, turnarounds and global mergers and acquisitions. Mr. Shah implemented “Think Global and Act Local” methodologies, utilizing operational and cultural experience in areas of IT strategy, omnichannel, business development and governance in more than 20 countries across the Americas, Australia, Europe, Asia and Africa. Mr. Shah holds a bachelor’s degree in computer science from Bombay University, a master of business administration degree in international marketing/short-term finance from the New York Institute of Technology, and an executive education certificate in digital marketing strategies for digital economy from the Wharton School.
Jacob Walthour Jr. - CEO, Blueprint Capital Advisors - Economic, Racial And Social Equity Advocacy
Progress, Potential, and Possibilities
05/26/21 • 41 min
Jacob Walthour, Jr. is the CEO and Co-Founder of the investment firm Blueprint Capital Advisors, which offers investment advisory and portfolio management services, managing $1.2 billion of clients wealth. Mr. Walthour has over 30 years of experience in capital markets, traditional and alternative asset management. Prior to founding Blueprint, Mr. Walthour served as Vice Chairman of Product and Business Development at the investment management division of Cowen & Company, also serving on the firm’s Management Committee. Previously, Mr. Walthour served as Managing Director of Cliffwater LLC, a leading provider of alternatives consulting, serving on the firm’s Investment Committee and responsible for client consulting. Prior to joining Cliffwater, Mr. Walthour was a Partner and Managing Director at Citadel Investment Group where he managed the firm’s North American distribution effort. Mr. Walthour received his BA cum laude from the Nelson Rockefeller School at the State University of New York at Albany. Mr. Walthour serves on several corporate boards including Parkview Capital Credit, Inc., Transportation Demand Management LLC. and chaired Ebony Media Holdings through its recent sale. He has also served, or is currently serving, on the boards of several non-profit and philanthropic organizations including the Investment Committee for $7 billion Margaret A. Cargill Philanthropy, the Investment Subcommittee of the Girl Scouts of the United States of America, as a Director of the Robert F. Kennedy Center for Human Rights, Trustee for the New York Foundation for the Arts, Director of New York Cares and Trustee of the ECLC School for children and adults with learning disabilities. Mr. Walthour has been a frequent speaker at pension, hedge fund, and alternative investment conferences, and has been featured on CNBC and contributed to a variety of articles in Vanity Fair, The Wall Street Journal, Institutional Investor Alpha, and Bloomberg.
Dan Addario - Former Special Agent In Charge - U.S. DEA - New Ideas For The Global Drugs Crisis
Progress, Potential, and Possibilities
05/02/21 • 34 min
According to the U.S. National Survey on Drug Use and Health, an estimated 20 million American adults battled a full-fledged substance use disorder in 2017. Drug abuse and addiction cost American society more than $740 billion annually in lost workplace productivity, healthcare expenses, and crime-related costs. Mr. Dan Addario spent 3 decades with the U.S. Drug Enforcement Agency (DEA), rising to the role of Special Agent in Charge, the highest-ranking field agent for the DEA under five presidents, heading up anti-drug operations in 13 countries throughout South American, South East Asia, as well as in the U.S. Dan started his career in Philadelphia as one of the nation’s first narcotics undercover agents in 1954 and was involved in the capture of some of the world’s most notorious drug lords, and was even on scene when Panamanian strongman Manuel Noriega was captured by US forces. Dan's list of accomplishments consists of, but is not limited to: - A cultivation of the U.S. strategic relationship with the Panamanian leader, Manuel Noriega, who at the time, was head of police in Panama and fighting the war on drugs with the U.S. , - The chase and capture Auguste Joseph Ricord, the French-Corsican heroin trafficker and one of the founding members of the French Connection, immortalized in the 1970s Gene Hackman movie, - Infiltrating the center of the “Golden Triangle” opium empire of Burmese opium king Khun Sa, - The major drug bust, round up and arrest of dozens of Hell’s Angels, including their head Sonny Barger - The destruction of a dozen of drug guru Timothy Leary’s LSD labs - The drug arrest Ray Charles - Working with special counsel Robert Mueller, Frank Sinatra, and Watergate figures including John Dean and Gordon Liddy Sadly, in 1993 the very scourge he was battling came home and was responsible for taking the life of his son Daniel due to opiate addiction. After he retired from the DEA, Mr. Addario spent some time in the news business working for a San Francisco news station. He has recently published a book entitled "Chasing the Dragon: How to Win the War on Drugs" where is recounts his long history and experience as well as puts forth a range of new ideas as the drug war continues in this millennium.
Dr. Azra Raza - Anticipate, Find, And Destroy The FIRST Cancer Cell; STOP The Disease In Its Tracks
Progress, Potential, and Possibilities
03/23/21 • 67 min
As we approach the end of 2020, according to the U.S. National Cancer Institute (NCI), we have had approximately 1,806,590 new cases of cancer diagnosed in the United States, with 606,520 deaths. Cancer continues to be the leading causes of death worldwide. In 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Dr. Azra Raza, MD, is the Chan Soon-Shiong Professor of Medicine, in the Department of Medicine, Division of Hematology / Oncology, and Director of the Myelodysplastic Syndrome (MDS) Center, at the Columbia University Medical Center. Previously, Dr. Raza was the Chief of Hematology-Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts. Dr. Raza is an international authority on pre-leukemia / MDS, and acute leukemia, and is both a physician and scientist who divides her time equally between caring for patients and supervising a state-of-the-art basic research lab which is well-funded by multiple large grants. Dr. Raza started collecting blood and marrow samples on her patients in 1984 and now her Tissue Bank, the largest and oldest in the country with over 60,000 samples, is considered a unique national treasure. Dr. Raza has published her original clinical and basic research comprising over 300 peer-reviewed manuscripts in high profile journals like Nature, New England Journal of Medicine, Cell, Molecular Cell, Cancer Research, Blood, Leukemia. She has published over 1,000 abstracts, dozens of book chapters and edited a book devoted to MDS, entitled "Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia: Directions for the New Millennium". Dr. Raza is the recipient of numerous awards including The Hope Award in Cancer Research 2012 (shared with the Nobel Laureate Dr. Elizabeth Blackburn). She was named as one of the 100 Women Who Matter by Newsweek Pakistan. Dr. Raza is a member of the Founder Group designing Breakthrough Developments in Science and Technology with President Bill Clinton, and was involved with Vice President Joe Biden to discuss the Cancer Moonshot initiative. Dr. Raza is the author of the recently published book "The First Cell: And the Human Costs of Pursuing Cancer to the Last". In addition to her scientific accomplishments, Dr. Raza is a dedicated reader of Urdu literature, and co-authored a book on the poems of the 19th century Indian poet Ghalib, entitled "Ghalib: Epistemologies of Elegance".
Dr. Richard Burt MD - Pioneering Hematopoietic Stem Cell Transplants (HSCT) For Autoimmune Disorders
Progress, Potential, and Possibilities
01/09/23 • 58 min
Dr. Richard K. Burt MD ( https://astemcelljourney.com/about/drrichardburt/ ) is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University where he served as Chief of Immunotherapy and Autoimmune Diseases, and CEO of Genani Biotechnology. Dr. Burt endeavored for thirty-five years, first with animal models and then with some of the world’s first clinical trials, to bring the field of stem cell and cellular therapy to the patient’s bedside. Dr. Burt has published more than 145 mostly first author articles and is the Editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH) $10,000,000 multi-center contract to develop stem cell clinical trials for autoimmune diseases. Dr. Burt performed America’s first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn’s disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world’s first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Dr. Burt has been awarded Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the Van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Dr. Burt was presented in Vatican City, Rome with the “Keys to the Vatican”, was speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates, and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Dr. Burt was recognized by Science Illustrated for accomplishing one of the Top 10 medical breakthroughs for the next ten years, and by Scientific American as one of the Top 50 individuals, teams, or organizations for improving humanity and outstanding leadership. His newest book is entitled "Everyday Miracles - Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant".
Dr. Ruth Tal-Singer, Ph.D. & Dr. Scott M. White, M.D. - ENA Respiratory - Transforming The Treatment & Prevention Of Respiratory Viral Infections Via Innate Immune Modulation
Progress, Potential, and Possibilities
09/27/23 • 30 min
ENA Respiratory ( https://enarespiratory.com/ ) is a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants. ENA Respiratory is based in Melbourne and Sydney, Australia Dr. Ruth Tal-Singer, Ph.D., Medicine Development Leader, ENA Respiratory, is an internationally recognized healthcare leader and clinical scientist with extensive Research and Development experience including recent roles as Vice President of Respiratory Medical Innovation R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals where during her career she led many projects that resulted in new insights, bringing new treatments to the market. She also formerly served as Chief scientific officer and CEO of the COPD Foundation, where she led the patient-centered research, education, and global community outreach advocacy organization focused on the prevention and early diagnosis and treatment of chronic lung diseases. Her vision led to the creation of World Bronchiectasis Day, observed on July 1. Dr. Tal-Singer’s idea resulted in global awareness of the under-researched and under-represented bronchiectasis disease in partnership with 20 other global patient advocacy, academic, and research organizations. As the leader of COPD360Net, the COPD Foundation’s digital health, medical devices, and therapeutics development accelerator network, she championed the partnership between ENA Respiratory and the COPD Foundation and served as a member of its Board of Directors on behalf of the COPD Foundation until March 31, 2023. Dr. Tal-Singer has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. As a researcher, Dr. Tal-Singer has authored 180+ peer-reviewed papers including highly cited scientific publications. She has a Doctor of Philosophy (PhD), Molecular Biology / Microbiology, from University of Pennsylvania, did post-doctoral work at the Wistar Institute, and continues to lecture at the Institute of Translational Medicine and Therapeutics at Penn. Dr. Scott M. White, M.D., Chief Medical Officer, ENA Respiratory, is an infectious diseases physician who has spent over 17 years working in the pharmaceutical and biotech industry. Most recently he served as Vice President Clinical Development for the infectious diseases therapeutic area of Inovio Pharmaceuticals where he was responsible for the clinical development of immunotherapeutic and prophylactic DNA-based vaccines. Prior to this he was a Physician Project Leader for GlaxoSmithKline. In this role he was accountable for several development programs spanning pre-candidate selection through early stage clinical development of assets in the therapeutic areas of infectious diseases, hematology, and dermatology. During this time at GlaxoSmithKline, in collaboration with AstraZeneca, the EU Innovative Medicines Initiative, and medical and scientific leaders throughout Europe, he led the establishment of COMBACTE; a European antibacterial clinical trial network supporting the development of antibiotics targeting resistant organisms. Dr. White has his M.D. from Pennsylvania State University College, and did an Infectious Diseases Fellowship at University of Pittsburgh School of Medicine.
Show more best episodes
Show more best episodes
FAQ
How many episodes does Progress, Potential, and Possibilities have?
Progress, Potential, and Possibilities currently has 582 episodes available.
What topics does Progress, Potential, and Possibilities cover?
The podcast is about Health & Fitness, Space, Neuroscience, Future, Research, Environment, Energy, Podcasts, Technology, Science and National Security.
What is the most popular episode on Progress, Potential, and Possibilities?
The episode title 'H.E. President Surangel S. Whipps, Jr. - Republic of Palau - Environment, Economy, Palauan People First' is the most popular.
What is the average episode length on Progress, Potential, and Possibilities?
The average episode length on Progress, Potential, and Possibilities is 50 minutes.
How often are episodes of Progress, Potential, and Possibilities released?
Episodes of Progress, Potential, and Possibilities are typically released every 15 hours.
When was the first episode of Progress, Potential, and Possibilities?
The first episode of Progress, Potential, and Possibilities was released on Dec 4, 2020.
Show more FAQ
Show more FAQ